If the company replied to emails and calls the price would be $1.
I had similar experiences.
Company is totally focused on its tasks and assumes market will take care of itself.
Big pharma candidate would not have requested second lot of tests if it were not interested.
Great to see CEO decided to produce test internally. Apparantly not very costly to do and its right up their alley.
I run a model on some of these small cap tech/bio stocks. This tops my list.
Ann: Proteomics gaining strong traction in Analytical Services-PIQ.AX, page-9
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
-0.050(4.67%) |
Mkt cap ! $133.6M | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.12 | $1.02 | $401.2K | 373.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1130 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 8870 | 1 |
View Market Depth
| Last trade - 15.45pm 11/07/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |